ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2164

Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies

Masashi Taniguchi1, Ran Nakashima1, Nobuo Kuramoto1, Kosaku Murakami1, Motomu Hashimoto2, Hajime Yoshifuji1, Masao Tanaka2, Koichiro Ohmura1 and Tsuneyo Mimori1, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: dermatomyositis, polymyositis and prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Muscle Biology, Myositis and Myopathies Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-aminoacyl-tRNA synthetase antibodies (Abs), which mainly consists of anti-Jo1, PL-7, PL-12, EJ, OJ and KS, are the most common myositis-specific autoantibodies (MSAs). It has been recognized that anti-synthetase Abs are associated with characteristic clinical phenotype, chronic disease course, good response to initial glucocorticoid therapy and relatively good prognosis. However, we sometimes encounter such patients that are resistant to immunosuppressive therapies and have poor prognosis. Therefore, we retrospectively analyzed prognostic factors in polymyositis(PM)/ dermatomyositis (DM) patients with anti-synthetase Abs.

Methods: We retrospectively examined medical records of 121 PM/DM patients with anti-synthetase Abs who had been treated in our hospital from April 2001 to December 2016 (32 with Jo-1, 26 with PL-7, 25 with EJ, 21 with PL-12, 11 with OJ, 4 with KS, 1 with PL7 and PL12, 1 with Jo-1 and PL12). Anti-ARS Abs were examined with RNA immunoprecipitation using Hela cells. We analyzed the prognostic factors with univariate cox proportional hazards regression analysis. Next, we analyzed each of them with multivariate analysis. Comparison of survival time among each anti-synthetase Abs, we used Kaplan-Meier method.

Results: The 10-year survival of whole anti-synthetase Abs-positive PM/DM patients was 74.7%. 21 patients died of interstitial pneumonia (n=8), infection (n=2), malignancy (n=4), thrombotic thrombocytopenic purpura (TTP) (n=1), alveolar hemorrhage (n=2), subarachnoid hemorrhage (n=1), unknown cause (n=3). In univariate analysis, old age at onset , male , anti-PL-7 ,high values of lactate dehydrogenase, high dose of maintenance glucocorticoid, no use of immunosuppressant were found to be significant poor prognostic factors. Multivariate analysis revealed 5 significant poor prognostic factor, anti-PL-7 Ab, old age at onset , male , high dose of maintenance glucocorticoid , no use of immunosuppressant. In Kaplan-Meier analysis, it was suggested that anti-EJ-positive patients may have poor prognosis after more than 15 years follow-up as well as anti-PL-7-positive patients.

Conclusion: The poor prognostic factors in anti-ARS-positive patients were anti-PL-7 Ab, old age at onset , male , high dose of maintenance glucocorticoid , no use of immunosuppressant. Moreover, anti-EJ have poorest survival after more than 15 years follow-up as well as anti-PL-7.

 


Disclosure: M. Taniguchi, None; R. Nakashima, None; N. Kuramoto, None; K. Murakami, None; M. Hashimoto, None; H. Yoshifuji, None; M. Tanaka, None; K. Ohmura, None; T. Mimori, None.

To cite this abstract in AMA style:

Taniguchi M, Nakashima R, Kuramoto N, Murakami K, Hashimoto M, Yoshifuji H, Tanaka M, Ohmura K, Mimori T. Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/prognostic-factors-in-polymyositis-dermatomyositis-patients-with-anti-synthetase-antibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prognostic-factors-in-polymyositis-dermatomyositis-patients-with-anti-synthetase-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology